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Abstract
Background: Stromal mesenchyme cells play an important role in epithelial differentiation and likely in
cancer as well. Induction of epithelial differentiation is organ-specific, and the genes responsible could be
identified through a comparative genomic analysis of the stromal cells from two different organs. These
genes might be aberrantly expressed in cancer since cancer could be viewed as due to a defect in stromal
signaling. We propose to identify the prostate stromal genes by analysis of differentially expressed genes
between prostate and bladder stromal cells, and to examine their expression in prostate cancer.
Methods: Immunohistochemistry using antibodies to cluster designation (CD) cell surface antigens was
first used to characterize the stromas of the prostate and bladder. Stromal cells were prepared from either
prostate or bladder tissue for cell culture. RNA was isolated from the cultured cells and analyzed by DNA
microarrays. Expression of candidate genes in normal prostate and prostate cancer was examined by RT-
PCR.
Results: The bladder stroma was phenotypically different from that of the prostate. Most notable was the
presence of a layer of CD13+ cells adjacent to the urothelium. This structural feature was also seen in the
mouse bladder. The prostate stroma was uniformly CD13-. A number of differentially expressed genes
between prostate and bladder stromal cells were identified. One prostate gene, proenkephalin (PENK),
was of interest because it encodes a hormone. Secreted proteins such as hormones and bioactive peptides
are known to mediate cell-cell signaling. Prostate stromal expression of PENK was verified by an antibody
raised against a PENK peptide, by RT-PCR analysis of laser-capture microdissected stromal cells, and by
database analysis. Gene expression analysis showed that PENK expression was down-regulated in prostate
cancer.
Conclusion: Our findings show that the histologically similar stromas of the prostate and bladder are
phenotypically different, and express organ-specific genes. The importance of these genes in epithelial
development is suggested by their abnormal expression in cancer. Among the candidates is the hormone
PENK and the down-regulation of PENK expression in cancer suggests a possible association with cancer
development.
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Background
The functional development of the prostate is governed by
stromal mesenchyme induction and epithelial response.
This stromal/epithelial interaction was demonstrated by
heterotypic tissue recombinants engrafted in animal hosts
in which the stromal element dictated the organogenesis
of the implanted epithelial component [1]. For example,
adult human bladder epithelial cells can be transdifferen-
tiated into prostatic structures by prostate inductor [2]. In
that study, neonatal rat seminal vesicle mesenchyme
induced adult human urothelial cells to produce glandu-
lar structures resembling the prostate histologically and
functionally, in which secretory-like cells in these struc-
tures produced prostate-specific antigen (PSA). The induc-
tive mechanism is evolutionarily conserved because it was
demonstrated with heterospecific mouse/human recom-
binants. Besides stromal/epithelial interaction, morpho-
genesis and functional cytodifferentiation are dependent
on interactions between epithelium and basement mem-
brane and the extracellular matrix [3]. Prostate develop-
ment is also under hormonal control and the influence of
androgen is primarily mediated by the stromal cells [4].
There is also evidence that stromal/epithelial interaction
is involved in the differentiative development of other
organs like the gut and kidney [5,6].
We postulate that organ-specific stromal cell genes are
important factors in organ development. In order to iden-
tify these genes, we compared the expression profile of
prostate stromal cells with that of bladder stromal cells.
Since stromal cells of the two organs appear histologically
indistinguishable we first used immunohistochemistry
with a panel of CD antibodies to look for differences.
Next, we used DNA array analysis to determine genes that
are differentially expressed by the two stromal cell types.
Due to experimental demands of RNA quantity we used
stromal cells cultured in vitro. The organ specificity of the
candidate genes was verified with RT-PCR analysis. Given
the importance of stromal cells in epithelial differentia-
tion, it is possible that diseases such as cancer of the epi-
thelial cells could arise from defects in or a loss of stromal
influence. We, therefore, also examined the expression of
prostate stromal cell genes in cancer.
Methods
Prostate and bladder tissue, and stromal cell culture
Prostate tissue specimens were obtained from patients
undergoing radical prostatectomy for their cancer treat-
ment. Prostate metastases were obtained from patient
donors after death through the Department of Urology
tumor acquisition necropsy program [7]. Bladder tissue
specimens were obtained from patients undergoing cysto-
prostatectomy for their bladder cancer. The cellular com-
position of these specimens was determined by
histological examination of tissue block sections. For stro-
mal mesenchyme (fibromuscular) cells, only specimens
taken from cancer-free areas of the resected organs were
used. Cultures were started either by placing tissue pieces
on plates or by plating single cells prepared by tissue
digestion with collagenase [8]. Briefly, fresh tissue speci-
mens were minced and placed in RPMI-1640 media sup-
plemented with 5% fetal bovine serum (FBS), 10-8 M
dihydrotestosterone (DHT), and digested with type I col-
lagenase (Invitrogen, Carlsbad, CA, USA) overnight at
room temperature. The digested tissue was filtered
through a Falcon 70-µm filter (Becton-Dickinson, Frank-
lin Lakes, NJ, USA) and aspirated with a 18-gauge needle.
Stromal (STROM) and epithelial (EPI) cell types were par-
titioned by centrifugation in a discontinuous Percoll den-
sity gradient: STROM at ρ = 1.035 and EPI at ρ = 1.07.
Prostate or bladder STROM cells from the Percoll gradi-
ents were cultured in RPMI-1640 supplemented with 10%
FBS and 10-8 M DHT. Cells were trypsinized and serially
passaged, and harvested at the 4–5th passage. Light micro-
scopy was used to check the cell morphology. For confir-
mation, the cells were tested for expression of epithelial
cytokeratins (none) and CD markers (CD90 positive) by
immunohistochemistry and other cell type-specific mark-
ers by reverse transcriptase polymerase chain reaction (RT-
PCR) as described in a previous report [8]. Percoll gradi-
ents were used additionally to remove contaminant epi-
thelial cell types, if any, before RNA isolation for array
analysis. The use of human material for research was
approved by the Institutional Review Board of the Univer-
sity of Washington.
Immunohistochemistry
Immunohistochemistry specifications, including experi-
mental design, staining, and image analysis, were compli-
ant with Minimum Information Specification For In Situ
Hybridization and Immunohistochemistry Experiments
(MISFISHIE) [9]. Serial 5-µm thin sections were prepared
from frozen blocks of prostate and bladder tissue, and
processed for immunostaining using a commercial kit
(Vector Labs, Burlingame, CA, USA). Antibodies to CD13
(clone WM15) and other CD molecules (BD-PharMingen,
San Diego, CA, USA) were used at a starting concentration
of 8 ng/µl. The use of these antibodies has been described
in previous reports [10,11]. A custom-made anti-PENK
(proenkephalin) rabbit polyclonal antibody (Abgent, San
Diego, CA, USA) was used at 3.5 ng/µl. The antibody was
raised against a synthetic PENK peptide – C*TGDNRER-
SHHQDGSDNE – from amino acid residues T163 to
E179, plus an extra C for conjugation to carrier [12]. The
immunoreaction was carried out at room temperature for
30 min. Biotinylated anti-mouse IgG, anti-mouse IgM, or
anti-rabbit IgG was used for chromogen detection. Immu-
nostained sections were imaged with Olympus BX41
microscope (Melville, NY, USA) equipped with MircoFire
digital camera (Optronics, Goleta, CA, USA). CompositeBMC Urology 2005, 5:17 http://www.biomedcentral.com/1471-2490/5/17
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images were constructed with Photoshop CS (Adobe Sys-
tems, San Jose, CA, USA) and all source images are availa-
ble at our SCGAP website [13].
Gene expression analysis by DNA microarray
A 40K human cDNA-gene chip (IMAGE Consortium, rep-
resenting 35,013 UniGENE clusters) was used for gene
expression analysis. Microarray fabrication, RNA prepara-
tion, labeling with Cy3/Cy5 dyes (Amersham Biosciences,
Piscataway, NJ, USA), hybridization, and washing have
been described previously [14]. Total cellular RNA was
prepared and its quality and concentration were deter-
mined with Agilent 2100 Bioanalyzer (Agilent Technolo-
gies, Palo Alto, CA, USA). Approximately 50 µg RNA was
used for labeling. The array experiment was performed in
quadruplicate and a dye-flip was also included. Raw data
was processed, log ratios were estimated, and the signifi-
cance of change was determined by a maximum likeli-
hood method [14]. Differential expression was
statistically assessed by a λ value, and values > 35 were
considered significant. Expression was confirmed by RT-
PCR using gene-specific primer pairs and RNA prepared
from a different batch of cultured prostate and bladder
cells. Primer pair sequences for either prostate or bladder
genes used are listed in Table 1.
Laser-capture microdissection
Prostate stromal cells were isolated from tissue by laser-
capture microdissection (LCM). Eight-µm thick sections
of frozen tissue blocks were cut, immediately fixed in cold
95% ethanol, briefly stained with hematoxylin using His-
toGene Staining (Arcturus Bioscience, Mountain View,
CA, USA), and dehydrated in 100% ethanol followed by
xylene, as described in the Arcturus HistoGene LCM Fro-
zen Section Staining Kit. Around 5,000 stromal cells were
captured using Arcturus PixCell II machine. Following
microdissection, captured cells were lysed in Arcturus
RNA Extraction Buffer. RNA was isolated using Arcturus
PicoPure RNA Isolation Kit, and then treated with RNase-
Free DNase (Qiagen, Valencia, CA, USA). The RNA was
used to analyze by RT-PCR for PENK expression.
Gene expression analysis of stromal genes in cancer
Gene expression analysis of matched normal/non-cancer
and cancer of the prostate was analyzed by RT-PCR.
Tumor specimens were excised from cancer foci in surgi-
cally resected glands, and non-cancer specimens were
taken from cancer-free areas. The small pieces of tissue (~1
mm3) were placed in RNAlater (Ambion, Austin, TX, USA)
if not processed immediately, and were homogenized in a
lysis buffer. RNA was precipitated by isopropanol for CP
(prostate cancer or enriched for cancer) and NP (normal
prostate) cDNA synthesis as described previously [15].
Tumor specimens from necropsies (usually performed
within 3 h of death) were similarly processed. Because of
tumor necrosis, specimens that produced poor quality
RNA were not used. Primers for β2 microglobulin (B2M)
and smooth muscle actin (αSMA) were used to monitor
the suitability of the cDNA for analysis. Twenty NP and
CP pairs were tested.
Table 1: Primer pair sequences used in the study.
Gene 5' primer 3' primer
STC1 GACACTCAGGGAAAAGCATTCG CTCATGGGATGTGCGTTTGAT
PENK CAACTTCCTGGCTTGCGTAATG AGGAACTTCTTTGGAGTAACTTTCGC
BMP2 CGGTCTCCTAAAGGTCGACCA GTCACGGGGAATTTCGAGTTG
RAB27B GGTTTATAATGCACAAGGACCGAA CCACACACTGTTCCATTCGCT
MMP3 CTCACAGACCTGACTCGGTTCC ATCGATTTTCCTCACGGTTGG
GALNT7 CTCAAGTCTGCTCTCAGCGAATATG TTTTGGTAGATGTGTCCTACCCGA
TRO GACACTCAGGGAAAAGCATTCG CTCATGGGATGTGCGTTTGAT
RIS1 GTAAGCCCATTGAGTCCACGC TCACTTGGTCGCCACCCCCGA
ChGn TGCAGCAGTGCCTTTCGATAG GTCGAAATAAGATGAGCCGTTTGA
TNC CAGACATCACTGAAAATTCGGCTAC GCAAAGATTCTCAGTGTGTATTCCG
EDNRB GCAAACCGCAGAGATAATGACG TCAAGATATTGGGACCGTTTCG
STC2 CAAGTCATTCATCAAAGACGCCTT CCTTTCATTTCACCTCCGGATATC
BF ACTCCATGGTCTTTGGCCCAG AGTGGATTGCTCTGCACTCTG
GFRA1 ACAGCAGATTGTCAGATATATTCCGG GCGAGATCTGCAGATGTAATTCG
IMPA2 TAGCATTGGATTTGCTGTTCGAC TCCCGCCCATAGTTAATCGTCT
PTGIS GGCTACCTGACTCTTTACGGAATTG GGCTCTCACTCAGCACGCTATC
OSF2 CTGCTTATTGTTAACCCTATAAACGCC TTGCTCTCCAAACCTCTACGGAT
EST GAAGCAGAGCCATGACAATCG CCATGACTTCCATGACAATCGTC
B2M CACGTCATCCAGCAGAGAATGGAAAGTC TGACCAAGATGTTGATGTTGGATAAGAG
αSMA GCCTCTGGACGCACAACTGGCATCG GTTTGCTGATCCACATCTGCTGGAAGGBMC Urology 2005, 5:17 http://www.biomedcentral.com/1471-2490/5/17
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Results
CD phenotypes of prostate stroma vs. bladder stroma
Almost all the constituent cell types of the prostate and
bladder were identified by their particular complement of
CD molecules. Overall, the stromal mesenchyme (fibro-
muscular) cells of the prostate and bladder were shown to
share many of the CD molecules but there were differ-
ences as well. In particular, CD13 (aminopeptidase N)
staining differentiated two sub-domains of the bladder
lamina propria (Figure 1a). A region of not more than 10–
20 cells in depth, by our estimate, next to the urothelium
was positive for CD13 while the remainder of the lamina
propria was negative. The CD13-positive part was termed
superficial lamina propria by us. This CD13-positive
superficial lamina propria was also found in the mouse
bladder (Figure 1b). In contrast, the prostatic stromal cells
showed no staining, and expression of CD13 was local-
ized to the luminal epithelial cells as reported earlier (Fig-
ure 1c).
The reactivity of other CD antibodies is summarized in
Table 2 for the bladder superficial lamina propria, bladder
lamina propria, bladder muscularis, blood vessel smooth
muscle cells and prostate stroma. Although smooth mus-
cle cells are the principal cell types in these tissue struc-
tures they were distinguishable by their CD phenotypes.
Besides CD13, differences between prostate and bladder
stroma included CD51/61 (integrin αvβ3), CD56
(NCAM) – positive for prostate and negative for bladder,
CD107a (LAMP-1) – negative for prostate and positive for
bladder. In general, the bladder stromal mesenchyme
compartment appeared to contain multiple cell types,
such as CD13+ vs. CD13-, CD49a+ vs. CD49a- (integrin
α1), CD49d+ vs. CD49d- (integrin α4) compared to the
uniformly CD13-/CD49a+/CD49d- type in the prostate.
All immunohistochemistry data are available at SCGAP
website [13].
Organ-specific stromal mesenchyme cell genes
The CD immunohistochemistry results showed that stro-
mal cells of the prostate and bladder were different such
that a transcriptome profiling would likely uncover more
differentially expressed genes between them. Accordingly,
stromal cells were cultured from fresh tissue taken from
radical prostatectomy or cystoprostatectomy specimens.
Because of their poor plating efficiency, epithelial cells (if
present at the beginning) were outgrown by the stromal
cells under the culture condition used. CD phenotyping of
the resultant cultures showed previously that the prostate
and bladder cells could be distinguished (e.g., reactivity to
CD56) but a number of CD molecules, among them
CD13, were also expressed as a result of cell culture [8].
Thus, it was not possible to state if the resultant bladder
cells were derived from cells of the CD13+ superficial lam-
ina propria. RNA was obtained typically from ~106 cells
CD13 immunohistochemistry of the prostate and bladder Figure 1
CD13 immunohistochemistry of the prostate and bladder. 
(a) Human bladder: CD13 stains a subpopulation of stromal 
cells (black arrow) in the lamina propria. The partially 
denuded urothelium is indicated by the red arrow. (b) Mouse 
bladder: CD13 also stains a similar region (black arrow) in 
the mouse bladder as in the human bladder. (c) Human pros-
tate: CD13 stains only luminal epithelial cells (black arrow) of 
prostatic glands.BMC Urology 2005, 5:17 http://www.biomedcentral.com/1471-2490/5/17
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harvested at the log phase. A 40K cDNA array was used to
profile the transcriptomes of these cultured stromal cells.
The list of the differentially expressed genes identified
through this analysis is shown in Table 3, and differential
expression of these genes between prostate and bladder
was verified by RT-PCR (Figure 2). Among these was one
hormone, proenkephalin (PENK), and this was studied
further because hormones are likely important mediators
of intercellular communication and proenkephalin is
known to have a role in development. PENK was one of
genes that showed the highest fold in differential expres-
sion between prostate and bladder (Table 3).
Expression of PENK in prostate fibromuscular cells
The prostate stromal specific expression of PENK was ver-
ified by RT-PCR on stromal cells from tissue microdis-
sected by laser-capture (Figure 3a). In our separate study,
we had generated cell type-specific transcriptomes for
prostate CD26+ luminal cells, CD104+ basal cells, CD49a+
stromal cells, and CD31+ endothelial cells through cell
sorting and DNA array analysis (unpublished). Data anal-
ysis showed that PENK was expressed predominantly by
the stromal cells (Figure 3b). These results showed that
PENK expression was not due to cell culture.
Proenkephalin is known to be processed into opioid pen-
tapeptides, and these can be detected in the neural ele-
ments of the prostate by their specific antibodies [16]. The
stromal PENK gene product was apparently not processed
to the pentapeptide enkephalins as in neuronal cells. To
localize PENK expression on tissue, a PENK peptide frag-
ment was synthesized and used to immunize rabbits for
anti-PENK antibodies. Immunohistochemistry of anti-
PENK showed staining of stromal fibromuscular cells next
Table 2: CD phenotype of the prostate and bladder stromal fibromuscular cells.
bladder
superficial lamina 
propria
lamina propria muscularis blood vessel prostate stroma
CD13 + - + + -
C D 2 9 +++++
CD30 - - + - +/-
CD40 - - + - -
CD47 + + - + +/-
CD49a + scattered + scattered +/- + + uniform
CD49d - + scattered - - -
CD49e + scattered + scattered + - +
C D 4 9 f --- + * -
C D 5 1 / 6 1 - -+++
CD55 + + - - +
CD56 - - + - +
CD59 + + scattered - - +
C D 6 1 - -+++
CD69 - - +/- - +/-
C D 7 1 +++-+
CD79a + scattered + scattered + - +/-
CD81 + + ? - +
CD90 + + - + +
CD97 +/- - + - -
CD99R + + - - +
CD105 + - - + -
CD107a + + - - -
CD112 - + - - -
CD131 + scattered + scattered + ? +
CD151 + scattered + scattered + - +/-
CD184 +/- +/- + + +
CD243 - - + - -
* also CD109, CD31, CD34, CD93, CD141, LAP, LMP-1
+: stain
- : no stain
+/-: weak stain
? : equivocal (probably no stain)BMC Urology 2005, 5:17 http://www.biomedcentral.com/1471-2490/5/17
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Table 3: Organ-specific stromal mesenchyme cell genes. Listed are the candidates identified through array analysis. Fold difference in 
the last column of each grouping provides a rough estimate of the level of differential expression between the two cell types.
Prostate Stromal Genes Bladder Stromal Genes
Gene Description Gene Fold Gene Description Gene Fold
proenkephalin PENK 26.41 B-factor, properdin BF 44.23
stanniocalcin 1 STC1 20.86 argininosuccinate synthetase ASS 19.36
trophinin TRO 13.41 methylene tetrahydrofolate dehydrogenase (NAD+ 
dependent), methenyltetrahydrofolate 
cyclohydrolase
MTHFD2 19.04
RAB27B, member RAS oncogene family RAB27B 12.27 claudin 11 (oligodendrocyte transmembrane 
protein)
CLDN11 18.25
REV3-like, catalytic subunit of DNA polymerase z 
(yeast)
REV3L 10.68 interleukin 1, b IL1B 17.57
CD59 antigen p18-20 CD59 10.19 carbonic anhydrase XII CA12 16.49
matrix metalloproteinase 3 (stromelysin 1, 
progelatinase)
MMP3 10.06 pirin PIR 15.52
homolog of rat orphan transporter v7-3 NTT73 9.12 osteoblast specific factor 2 (fasciclin I-like) OSF-2 14.59
ras-induced senescence 1 RIS1 9.05 asparagine synthetase ASNS 12.96
chondroitin b1,4 N-acetylgalactosaminyltransferase ChGn 6.9 inositol(myo)-1(or 4)-monophosphatase 2 IMPA2 9.85
bone morphogenetic protein 2 BMP2 6.68 aldehyde dehydrogenase 1 family, member A1 ALDH1A1 9.48
sprouty homolog 4 (Drosophila) SPRY4 6.29 prostaglandin I2 (prostacyclin) synthase PTGIS 9.24
endothelin receptor type B EDNRB 5.46 aldo-keto reductase family 1, member C1 
(dihydrodiol dehydrogenase 1; 20-a (3-a)-
hydroxysteroid dehydrogenase)
AKR1C1 9.2
interleukin 7 receptor IL7R 5.44 BCL2 binding component 3 BBC3 9.06
tenascin C (hexabrachion) TNC 5.29 chemokine (C-X-C motif) ligand 12 (stromal cell-
derived factor 1)
CXCL12 8.65
tissue factor pathway inhibitor 2 TFPI2 5.13 activin A receptor, type II ACVR2 8.03
plasminogen activator PLAT 5.09 hyaluronan synthase 3 HAS3 7.34
transcription factor 21 TCF21 4.76 GDNF family receptor a1 GFRA1 7.12
KIAA1373 protein KIAA1373 4.42 activating transcription factor 5 ATF5 6.31
UDP-N-acetyl-a-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 7
GALNT7 4.25 protein tyrosine phosphatase, receptor type, D PTPRD 5.76
SEC14-like 2 protein (S. cerevisiae) SEC14L2 3.54 growth arrest-specific 1 GAS1 5.49
gap junction protein, a7, 45kDa (connexin 45) GJA7 3.21 Ca2+-dependent activator protein for secretion CADPS 5.25
paired-like homeodomain transcription factor 2 PITX2 4.86
tryptophanyl-tRNA synthetase WARS 4.76
phosphogluconate dehydrogenase PGD 4.56
CUG triplet repeat, RNA binding protein 2 CUGBP2 4.46
GATA binding protein 6 GATA6 4.4
collectin sub-family member 12 COLEC12 3.94
stanniocalcin 2 STC2 3.86
to the prostate epithelium whereas no staining of the stro-
mal cells adjacent to the urothelium was seen; although
staining was evident in the muscularis (Figure 4). This
result verified the differential expression of PENK between
prostate and bladder.
Down-regulation of PENK in prostate cancer
Patient-matched CP and NP specimens were used for this
analysis. The small size of the tissue was to ensure a purer
sample of cancer without non-cancer tissue. In the result
shown in Figure 5, the cancer specimens were primary
tumors graded with a Gleason score of 3+3 (G6), 3+4
(G7), or 4+5 (G9). The bone and liver metastasis speci-
mens were obtained from autopsies of donor patients.
PENK was detected in all three NP samples, but its level
was either decreased or undetectable in the CP and metas-
tasis samples. Expression of smooth muscle actin was
used as a control for the representation of stromal cells in
NP and CP.
Stanniocalcin 1 (STC1) was another gene of interests
identified through array analysis. It is also a hormone and
known to have a role in urologic organ development. Like
PENK, STC1 showed a large fold difference in expression
between prostate and bladder (Table 3). The RT-PCR
result of cultured cells showed that PENK was prostate-
specific whereas STC1 was expressed more in prostate
than bladder. The expression of STC1 was not signifi-
cantly different between NP and CP. It is interesting to
note that the prostate cancer cell lines, PC3 and C4-2, ana-BMC Urology 2005, 5:17 http://www.biomedcentral.com/1471-2490/5/17
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lyzed expressed STC1 (but not PENK), and it is thus pos-
sible that STC1 expression could be contributed by
epithelial cells as well.
Discussion
Our study showed that the stromal mesenchyme cells of
the prostate and bladder are phenotypically and genotyp-
ically different, although they are indistinguishable by
histomorphology. Within the bladder stroma of lamina
propria are cells that are either CD13+ or CD13-. The
CD13+ cells, in particular, constitute a discrete cell layer
next to the urothelium. Because of their proximity to the
urothelial cells these could be the cell type that functions
in bladder stromal/epithelial interaction. For our differen-
tial gene expression analysis we relied on cultured cells to
provide enough RNA for the array experiments. Since cell
culture alters gene expression as shown by the CD profile
of the cultured stromal cells [8], one question raised was
if they could still be representative of the stromal cells in
situ. For example, both cultured prostate and bladder stro-
mal cells are CD13+. It is possible that the bladder cells
were derived from the CD13+ cells of the superficial lam-
ina propria whereas the expression in prostate stromal
cells was de novo. Despite this caveat, cultured cells were
appropriate for our aim because cell-free conditioned
media is known to contain the inductive factors for epi-
thelial differentiation [17]. Furthermore, PENK expres-
sion in microdissected stromal cells confirmed that its
expression is not due to in vitro culture. More recently, we
have used cell sorting technology to determine the tran-
scriptomes of prostate cell types, including the CD49a+
stromal cells. The CD49a dataset allows us to further vali-
date the stromal expression of PENK.
Prostate stromal production of PENK is notable because
prostate luminal epithelial cells express CD10 (neutral
endopeptidase) [10,11], and CD10 is known to have
enkephalinase activity. Therefore, PENK and CD10 could
constitute a signaling pathway in prostate stromal/epithe-
lial interaction. PENK could potentially be one of the key
factors that mediate prostate differentiation. PENK expres-
sion was reported in the literature to be in embryonic
mesenchymal tissues during differentiation [18]. PENK is
normally processed into Met-enkephalin and Leu-
enkephalin, and antibodies to these pentapeptides could
detect expression at nerve endings in the prostate [16].
The non-neural cell-derived stromal PENK is not likely
processed to the known enkephalins. Our anti-PENK anti-
body showed that a PENK protein is indeed detectable in
the stromal cells of the prostate, and not in those of the
bladder. In the bladder, anti-PENK could detect a protein
in cells of the muscularis (and cells of blood vessels).
We hypothesized that cancer could be due to defects in
stromal/epithelial interaction, and expression of genes
like PENK could be altered in cancer. This was shown to
be the case by our RT-PCR analysis. In the tumor samples
analyzed there was down-regulation of PENK expression.
Previously, we showed that cancer epithelial cells are
CD10 negative [11], which would further suggest a link
between PENK and CD10 as defects in enkephalinase
activity may be associated with decreased PENK expres-
Expression of PENK in prostate stromal cell Figure 3
Expression of PENK in prostate stromal cell. (a) RT-PCR of laser-captured stromal cells. Cells were taken from non-cancer 
(NP), and PENK was detected in these cells. H2O was used as a negative control for the reaction. (b) PENK expression in 
sorted prostate cells. The various prostate cell types were sorted from tissue: CD26+ luminal cells, CD104+ basal cells, CD49a+ 
stromal cells, and CD31+ endothelial cells. Their transcriptomes were determined by microarray analysis using the Affymetrix 
Human Genome U133 Plus 2.0 GeneChips. PENK expression is localized to the CD49a+ stromal cells.
PENK
NP
stromal cells
Control
a. b.BMC Urology 2005, 5:17 http://www.biomedcentral.com/1471-2490/5/17
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Organ-specific stromal genes Figure 2
Organ-specific stromal genes. Shown are the results of the genes tested for their specificity, (cultured prostate vs. bladder stro-
mal cells). Differential expression is gauged by the band intensity of the PCR products. B2M is β2-microglobulin, which was 
used as a positive control, and H2O was used as a negative control for the reaction.
STC1
PENK
BMP2
RAB27B
MMP3
GALNT7
TRO
Bladder
Prostate
STC2
BF
GFRA1
IMPA2
PTGIS
OSF2
Unknown
B2M
Control
RIS1
ChGn
TNC
EDNRB
Bladder
ProstateBMC Urology 2005, 5:17 http://www.biomedcentral.com/1471-2490/5/17
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sion in cancer. Decreased PENK expression may be due to
gene methylation as reported in pancreatic cancer [19]. It
is likely that stromal/epithelial interaction involves more
than one gene, for example STC1. Stanniocalcins have a
function in neuronal cell differentiation by regulating cal-
cium and phosphate homeostasis [20]. STC1 is expressed
during mouse urogenital development and has a role in
the mesenchyme-epithelial interaction in organogenesis
[21]. Both STC1 and STC2 are reported to be secreted as
phosphoproteins from human fibrosarcoma, a tumor of
mesenchymal cells [22]. Unlike PENK, STC1 did not show
a clear altered pattern of expression between NP and CP.
The cancer expression of several other prostate stromal
genes was also investigated. GALNT7 and ChGn (Table 3),
for example, also showed a similar expression pattern for
NP and CP as PENK (unpublished). Further work will be
carried out to confirm these initial results.
Conclusion
The high throughput technology of genomics in conjunc-
tion with downstream analyses are critical to uncover the
molecular basis of cell-cell interaction in normal develop-
PENK immunohistochemistry of prostate and bladder Figure 4
PENK immunohistochemistry of prostate and bladder. (a) In prostate, the PENK antibody stains the stroma in a pattern that is 
similar to that by CD56 [13]. The smooth muscle wall of a large blood vessel is also stained (black arrow, left panel). Benign 
glands appear to be stained at the luminal surface, but this staining is likely non-specific because it was present in the control 
without the primary antibody (in which the stromal staining was not seen). (b) In bladder, both the urothelium (blue arrow) 
and stroma (red arrow) of the lamina propria are not stained. Stained are the muscle bundles of the muscularis propria.
a. Prostate
b. Bladder
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ment and cancer. In this study, we have identified candi-
date stromal cell genes for this process. Among these are
genes that encode known hormones that function in
intercellular signaling. The down-regulation of these
genes in cancer suggests their importance in normal devel-
opment.
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